Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Jun 2, 2023
Date Accepted: Sep 8, 2023

The final, peer-reviewed published version of this preprint can be found here:

Pilot Testing of an mHealth App for Tobacco Cessation in People Living With HIV: Protocol for a Pilot Randomized Controlled Trial

Brin M, Trujillo P, Haomiao J, Cioe P, Huang MC, Chen H, Qian X, Xu W

Pilot Testing of an mHealth App for Tobacco Cessation in People Living With HIV: Protocol for a Pilot Randomized Controlled Trial

JMIR Res Protoc 2023;12:e49558

DOI: 10.2196/49558

PMID: 37856173

PMCID: 10623232

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Pilot testing of an mHealth app for tobacco cessation in people living with HIV: the Sense2Quit study protocol

  • Maeve Brin; 
  • Paul Trujillo; 
  • Jia Haomiao; 
  • Patricia Cioe; 
  • Ming-Chun Huang; 
  • Huan Chen; 
  • Xiaoye Qian; 
  • Wenyao Xu

ABSTRACT

Background:

An estimated 40% of people living with HIV smoke cigarettes. Although smoking rates in the U.S. have been declining in recent years, people living with HIV continue to smoke at twice the rate of the general population. Mobile health (mHealth) technology is an effective tool for people living with a chronic illness, such as HIV, as currently 84% of households in the United States report that they have a smartphone. Although many studies have used mHealth interventions for smoking cessation, few studies have recruited people living with HIV who smoke.

Objective:

The objective of the pilot randomized controlled trial (RCT) is to examine the feasibility, acceptability, and preliminary efficacy of the Sense2Quit App as a tool for PWH who are motivated to quit smoking.

Methods:

The Sense2Quit study is a two-arm randomized controlled trial among people living with HIV who are motivated to quit smoking (n=60). Participants are randomized to either the active intervention condition which consists of an 8-week supply of nicotine replacement therapy, standard smoking cessation counseling, and access to the Sense2Quit mobile app and smartwatch, or the control condition which consists of standard smoking cessation counseling and a referral to the New York State Smokers’ Quitline.

Results:

Enrollment of study participants began in March 2023 and is expected to end in September of 2023. All data collection is expected to be completed by the end of December 2023. Results from this pilot study will be disseminated to the research community following completion of all data collection.

Conclusions:

This study protocol demonstrates a tailored intervention that has the potential to guide people living with HIV who smoke tobacco through their quitting process. Pilot testing of the Sense2Quit app will allow researchers to better understand the efficacy of tobacco cessation strategies and will help guide future mHealth research and development for people living with HIV who smoke. Clinical Trial: ClinicalTrials.gov NCT05609032


 Citation

Please cite as:

Brin M, Trujillo P, Haomiao J, Cioe P, Huang MC, Chen H, Qian X, Xu W

Pilot Testing of an mHealth App for Tobacco Cessation in People Living With HIV: Protocol for a Pilot Randomized Controlled Trial

JMIR Res Protoc 2023;12:e49558

DOI: 10.2196/49558

PMID: 37856173

PMCID: 10623232

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.